BTIG Research Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a research note issued on Monday,Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research’s target price indicates a potential upside of 168.46% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Wall Street Zen raised shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Monday, April 20th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $7.00 price target on shares of AC Immune in a research note on Friday, March 13th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.50.

AC Immune Stock Performance

Shares of NASDAQ:ACIU opened at $2.98 on Monday. The company has a market cap of $303.27 million, a price-to-earnings ratio of -3.63 and a beta of 1.65. The company has a 50-day moving average price of $2.93 and a 200-day moving average price of $3.09. AC Immune has a 12 month low of $1.51 and a 12 month high of $4.00.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Wednesday, April 29th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $0.33 million. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 110.92%. As a group, research analysts forecast that AC Immune will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On AC Immune

Hedge funds and other institutional investors have recently bought and sold shares of the business. EFG International AG purchased a new stake in AC Immune in the fourth quarter worth about $41,000. Private Advisor Group LLC purchased a new stake in AC Immune in the third quarter worth about $48,000. Sei Investments Co. purchased a new stake in shares of AC Immune during the second quarter valued at approximately $51,000. Goldman Sachs Group Inc. grew its holdings in shares of AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after buying an additional 5,920 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in shares of AC Immune during the third quarter valued at approximately $63,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.